Clinical trial
A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Refractory Neurologic Autoimmune Disease.
NCT07804004 is registered in ClinicalTrials.gov with CRISPR Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Refractory Neurologic Autoimmune Disease.
- Lead sponsor
- CRISPR Therapeutics
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- September 15, 2026
- Completion date
- December 30, 2029
- Enrollment
- 220 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune encephalitis, myelin oligodendrocyte glycoprotein antibody-associated disease, neuromyelitis optica, progressive multiple sclerosis (pms), stiff-person syndrome